Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02607618 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2
A Phase 3 study of Skin Structures and Soft Tissue Infections, sponsored by Motif Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 613
- Enrollment target
- 20
- Study locations
NCT02607618: Completed Phase 3 study of Skin Structures and Soft Tissue Infections, sponsored by Motif Bio.
NCT02607618 is a Phase 3 study of Skin Structures and Soft Tissue Infections that has completed, run by Motif Bio. The registered enrollment target is 613 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02607618, a Phase 3 study of Skin Structures and Soft Tissue Infections, has completed, sponsored by Motif Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 613 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
Primary Outcome
≥20% reduction in lesion size at 48 to 72 hours (Early Time Point \[ETP\]) compared to baseline in all randomized patients (ITT).
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Iclaprim
Study Locations (20)
California
- California - Anaheim
- California - Buena Park
- California - Chula Vista
- California - La Palma
- California - Long Beach
- St. Mary Medical Center ER - Long Beach
Florida
- Florida - Hollywood
- Florida - Miami
- Florida - Miami
Other
- Argentina - Buenos Aires
- Argentina - Buenos Aires
- Belgium - Brussels
Washington
- Washington - Kennewick
- Washington - Richland
Georgia
- Georgia - Columbus
Montana
- Montana - Butte
Nevada
- Nevada - Las Vegas
New Jersey
- New Jersey - Somers Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-08-08 |
| Phase | Phase 3 |
What the finished NCT02607618 record still lists
NCT02607618 is an interventional study that assigns participants to a tested intervention. The registered 613 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Skin Structures and Soft Tissue Infections appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.
NCT02607618 names 20 study sites across 10 states, led by California, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT02607618 about?
NCT02607618 is a clinical study titled "Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2". This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
What is the current status of trial NCT02607618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 613 participants. The study started on 2015-11. Estimated completion is 2017-08-08.
What conditions does trial NCT02607618 study?
This clinical trial studies the following conditions: Skin Structures and Soft Tissue Infections.
What interventions are being tested in trial NCT02607618?
The interventions under investigation include: Vancomycin (DRUG), Iclaprim (DRUG).
Who is sponsoring clinical trial NCT02607618?
This trial is sponsored by Motif Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02607618 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Montana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02607618's enrollment target sits among peer trials
613 598th of 2000 higher than 1,403 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia